Open in interactive viewer → charts, metric popovers & call review

LASE Corp Loads a Quantum Bullet, Still Has a Hole in the Barrel

A new chairman, a new name and a counter-drone laser weapon — wrapped around a $1.1 million quarter, a -39% gross margin and an unchanged going-concern warning.
LASE · Earnings Call · 2026-11-12

The Tell Is the Rename

Laser Photonics is now LASE Corp, and this is the first earnings call in the seat for founder-turned-Executive Chairman Dmitriy Nikitin (October) and CFO Tim Peterman (September). What follows is not a tweak to the story. It is a full re-founding of it around directed energy — a market Nikitin introduces through quantum mechanics, name-checks semiconductors, GLP-1 pills and additive manufacturing, and resolves into one product: Quantum Bullet, a laser anti-drone weapon aimed squarely at Group 1 and Group 2 drones. The economics argument is the sharpest thing on the call: “small drones have a big problem, and the economics are simple. Defending against a drone that costs a few hundred dollars with a missile that costs millions is not sustainable.” — Dmitriy Nikitin, CEO · 2026-11-12 First-generation hardware — the Laser Shield Anti-Drone, or LSAD — is to debut at I/ITSEC later this month, and management says it has already completed integration with Anduril's Lattice command-and-control platform, adding a mode where the weapon functions alone as a counter drone perimeter defender. That framing is genuinely company-unique. The keyword set for the quarter is dominated by things this company has never said before — quantum technology, particle beams, quantum level energy conversion, kinetic-weapon displacement. This is not sector boilerplate; it is a thesis statement.

What the Vision Has to Grow Out Of

Peterman's section is a sober counterweight, and he does not soften it. Net sales were $1.1 million, up 25% and the first year-over-year growth since Q4 2025 — but “although gross margin improved by 8 percentage points, it was still negative 39%.” — Tim Peterman, CFO · 2026-11-12 Selling product below cost at any volume is a production discipline problem, and he says so: gross margin and operating cash flow "still need significant work." The nine-month picture is worse than the quarter: net sales of $3.9 million against $5.8 million, with the shortfall blamed on a $1.1 million drop in laser cleaning products and services plus a $0.8 million decline in affiliate sales. Operating expenses fell 34% to $1.8 million; net loss narrowed 46% to $2.5 million. Cash and short-term investments reached $7.6 million, the highest quarter-end since September 2023, funded by $19.6 million of equity and warrant proceeds against $6.4 million of note repayments. And then the sentence that matters most: “we have not yet changed the company's view that substantial doubt remains about our ability to continue as a going concern.” — Tim Peterman, CFO · 2026-11-12 The prior fundamentals snapshot shows the shape of that problem — liabilities running at 115.6% of assets, up 58 percentage points year over year, with cash runway of roughly 0.9 quarters. Those figures predate the Q3 cash build, but nobody on the call disputed the direction.

The Business That Quietly Fell Out of the Story

Here is the contrast worth sitting with. For several prior quarters, laser cleaning was the company: it topped the keyword set in early 2024, dominated 2023, and CleanTech systems, robotic enclosures and distribution agreements with Fastenal were the answer to every revenue question. In the current quarter it appears as a line item explaining a decline. The pivot out of the legacy business is not rhetorical — it is arithmetic. What replaced it is a portfolio of acquisitions now being branded as three names: CMS Laser for pharma, Beamer Laser for industrial marking, and the legacy brand for cleaning. CMS is the most credible of the three, built on CO2 pill drillers for slow release and personalized medication, now being extended into UV marking and anti-counterfeit work, with orders in hand Nikitin expects to convert next year. Semiconductor is earlier still — a first system shipped, an exclusively licensed zero-width wafer-splitting technology at industrial prototype stage. Shareholders have heard the conversion promise before, and they said so out loud. On a 2023 call an investor asked: “why have sales declined? When we've been going to the trade shows, we haven't heard — we keep hearing this remarkable amount of opportunities for our lasers and yet the sales aren't there at all. When and how are we going to turn the ship around?” — Chuck Lipson, Analyst · 2023-08-17 A year later the question sharpened: “it appears many of these sales are one and done test orders, and they haven't led to anything more substantial.” — Brian Siegel, Analyst or Investor (inferred from context) · 2024-04-15 Management fell back then on the six-month marketing plus six-month sales-cycle defense. It is now three years later, and defense is again the answer to a revenue question.

This market is still in its infancy, and revenue at this stage is unpredictable.

Dmitriy Nikitin, CEO · 2026-11-12
That is unusually candid, and it is the most honest sentence on the call. It is also a direct contradiction of the prior era's confident "good results in the near future" patter.

Right Theme, Crowded Door

The global tape says the drone-defense wave is real and recently arrived. The market's curated keyword set put the Defence Drone Initiative into the top-75 in the latest quarter, and the reporter feed shows it in the same breath at DPRO and FLT.TO, alongside small drone supply-chain chatter and a dense cluster of counter-UAS and air-defense language across aerospace names. LASE is not early to a private insight; it is arriving at a door many others are pushing on. Where it differs is the stated reason it can win. Nikitin argues incumbents are anchored to the platforms directed energy would displace: “we do not depend on selling the weapons that our future technologies may replace.” — Dmitriy Nikitin, CEO · 2026-11-12 That is a real structural argument, and it is the same argument every small disruptor makes. The disconfirming evidence is that the price tape for this name is absent from the data here, so there is no market verdict to check the thesis against — and at a sub-$40 million market cap, a federal contract headline would move the equity far more than any product milestone. The test is now auditable rather than rhetorical. I/ITSEC at month-end produces either a live demo and program conversations, or another trade-show story. The fourth quarter must show gross margin climbing off negative 39%, the CMS pharma orders converting, and cash burn continuing to shrink from $2.7 million in Q3 toward the stated cash flow breakeven target. Nikitin closed with an uncharacteristically modest line for a man who opened on quantum mechanics: “investors' confidence is earned through actions, not promises.” — Dmitriy Nikitin, CEO · 2026-11-12 After three years of the same conversion question, the market will hold him to it.